Osta Biotechnologies Inc.
TSX VENTURE : OBI

Osta Biotechnologies Inc.

February 09, 2010 17:06 ET

Osta Biotechnologies Announces $2.5 Million Private Placement Led by Sherbrooke Street Capital

MONTREAL, QUEBEC--(Marketwire - Feb. 9, 2010) -

THE ISSUE OF THIS PRESS RELEASE IS LIMITED TO CANADA ONLY. THIS PRESS RELEASE SHOULD NOT BE ISSUED IN THE UNITED STATES THROUGH U.S. NEWS WIRE AGENCIES.

Osta Biotechnologies Inc. (TSX VENTURE:OBI) is pleased to announce that it has engaged Sherbrooke Street Capital Inc. (SSC) as its exclusive agent for a best-efforts private placement of a maximum of 17,857,143 units at a price of $0.14 per unit, for maximum gross proceeds to Osta of $2.5 million. Each unit will consist of one common share and one-half of a common share purchase warrant. Each whole warrant will entitle the holder to acquire one additional common share at a price of $0.22 for a period of two years from the closing of the private placement. The issue price of $0.14 was negotiated by Osta and (SSC) in the context of the market.

The units will be sold to "accredited investors" in Canada and the United States on a prospectus-exempt basis. Closing of a first tranche of the private placement is expected to occur shortly.

In connection with the private placement, (SSC) will receive a fee equal to up to 7% of the gross proceeds of the offering. In addition, Osta will issue a non-transferable broker warrant to (SSC), entitling it to purchase a number of common shares of Osta equal to up to 7% of the number of common shares sold in the private placement. The broker warrant will be exercisable at a price of $0.22 per common share for a period of two years from the closing of the private placement. 

The private placement is subject to regulatory approval, including that of the TSX Venture Exchange, and the signing of a definitive Agency Agreement between Osta and (SSC).

The securities issued in connection with the private placement will be subject to a four-month hold period under the policies of the TSX Venture Exchange and applicable securities legislation.

The net proceeds from the private placement will be used by Osta for research and development, as well as for working capital and general corporate purposes.

About Osta Biotechnologies Inc.

Osta is a biopharmaceutical company listed on the TSX Venture Exchange currently focusing on developing therapeutics for Cancer and Alzheimer's disease.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Osta Biotechnologies Inc.
    Dr. Ajay Gupta
    Chairman & CEO
    (514) 626-9519